Dark

Check out our Level2View

RXDX
Prometheus Biosciences, Inc. Common Stock
stock NASDAQ

Inactive

Jun 15, 2023

199.92USD+0.090%(+0.18)1,860,653

Pre-market

0.00USD-100.000%(-199.74)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 12, 2022

08:30AM EST - Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - GlobeNewswire Inc

Jan 5, 2022

08:30AM EST Prometheus Biosciences to Present at the 40th Annual J.P. Morgan GlobeNewswire Inc

Jan 3, 2022

08:05AM EST Prometheus Biosciences Reports Received First Preclinical Milestone Payment From Dr. Falk Pharma Related To Collab For PR600; Sees Investigational New Drug Application For PR600 In Q3'22 Benzinga

08:00AM EST Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and GlobeNewswire Inc

Dec 13, 2021

10:48AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021 Benzinga

09:52AM EST RBC Capital Initiates Coverage On Prometheus Biosciences with Outperform Rating, Announces Price Target of $46 Benzinga

Dec 8, 2021

11:27AM EST Analyst Ratings For Prometheus Biosciences Benzinga

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 Benzinga

07:31AM EST Wells Fargo Initiates Coverage On Prometheus Biosciences with Overweight Rating, Announces Price Target of $42 Benzinga

05:13AM EST Oppenheimer Upgrades Prometheus Biosciences to Outperform, Raises Price Target to $50 Benzinga

04:44AM EST SVB Leerink Maintains Outperform on Prometheus Biosciences, Raises Price Target to $47 Benzinga

Dec 7, 2021

07:19AM EST Prometheus Biosciences Reports Positive Topline Results From Phase 1 Trial Of PRA023 In Healthy Volunteers RTTNews

07:06AM EST Prometheus Biosciences Reports Topline Phase 1 Data On PRA023; Phase 1 Trial Achieved Primary Objective Of Safety And Tolerability And Demonstrated Favorable Outcomes On Other Key Endpoints Benzinga

07:00AM EST Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity GlobeNewswire Inc

Nov 15, 2021

11:20AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021 Benzinga

10:52AM EST 10 Biggest Price Target Changes For Monday Benzinga

10:46AM EST Oppenheimer Downgrades Prometheus Biosciences to Perform Benzinga

10:46AM EST SVB Leerink Maintains Outperform on Prometheus Biosciences, Raises Price Target to $43 Benzinga

Nov 12, 2021

08:00AM EST - Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 - GlobeNewswire Inc

Nov 2, 2021

08:00AM EDT Prometheus Biosciences to Present at Upcoming Investor Conferences GlobeNewswire Inc

Oct 12, 2021

04:04PM EDT Prometheus Biosciences To Present At Jefferies Virtual Next Generation IBD Therapeutics Summit Oct. 19 Benzinga

04:01PM EDT Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021 at 11:30 a.m. ET. GlobeNewswire Inc

Oct 5, 2021

10:14AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021 Benzinga

05:57AM EDT Oppenheimer Initiates Coverage On Prometheus Biosciences with Outperform Rating, Announces Price Target of $35 Benzinga

Aug 23, 2021

04:55PM EDT Prometheus Biosciences Names Mark C. McKenna To Succeed Tadataka Yamada As Chairman Benzinga

Aug 11, 2021

04:15PM EDT Prometheus Biosciences Q2 EPS $(0.49) Up From $(5.93) YoY, Sales $326.00K Up From $179.00K YoY Benzinga

04:01PM EDT - Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohns disease (CD) - GlobeNewswire Inc

Aug 5, 2021

07:40AM EDT Phathom Pharma, Prometheus Biosciences Chair Passed Away Benzinga

07:30AM EDT Prometheus Biosciences, Inc. (Nasdaq: RXDX), with great sorrow announced today that its Chairman of the Board, Tadataka (Tachi) Yamada, M.D., KBE, passed away unexpectedly on August 4, 2021. GlobeNewswire Inc

Aug 2, 2021

08:06AM EDT Prometheus Biosciences Announces Initiation Of APOLLO-CD Phase 2a Clinical Trial Of PRA023 In Moderate-To-Severe Crohn's Disease Benzinga

08:00AM EDT Prometheus Biosciences Announces Initiation GlobeNewswire Inc

Jul 19, 2021

08:11AM EDT Prometheus Biosciences Announces Initiation Of Global Phase 2 Clinical Trial Of PRA023 In Moderate-To-Severe Ulcerative Colitis Benzinga

08:00AM EDT -First precision approach to IBD by utilizing a companion diagnostic to identify patients- GlobeNewswire Inc

Jul 15, 2021

08:00AM EDT Prometheus Biosciences to Host Virtual R&D Day for Investors on GlobeNewswire Inc

Jun 23, 2021

04:44AM EDT 44 Biggest Movers From Yesterday Benzinga

Jun 21, 2021

09:06AM EDT Prometheus Biosciences Says Achieves Milestone Payment Of $10M From Dr. Falk Pharma GmbH Benzinga

09:00AM EDT -Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600- GlobeNewswire Inc

Jun 17, 2021

08:33AM EDT The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme Benzinga

Jun 16, 2021

05:02AM EDT 44 Biggest Movers From Yesterday Benzinga

May 25, 2021

04:05PM EDT Prometheus Biosciences to Present at 2021 Jefferies Virtual GlobeNewswire Inc

May 17, 2021

08:28AM EDT Prometheus Biosciences Appoints Fred Hassan To Its Board RTTNews

08:00AM EDT Fred Hassan, Former CEO of Schering-Plough and Former Chairman of GlobeNewswire Inc

May 14, 2021

04:01PM EDT Prometheus Biosciences to Present at 2021 RBC Capital Markets GlobeNewswire Inc

May 13, 2021

04:01PM EDT -PRA023, an anti-TL1A mAb, on track to initiate Phase 2 study for Ulcerative Colitis and Phase 2a study for Crohns Disease in 3Q 2021- GlobeNewswire Inc

Apr 23, 2021

07:28AM EDT The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs Benzinga

Apr 22, 2021

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 7, 2021

10:38AM EDT TipRanks Posts On Golden Nugget, Prometheus Biosciences: 'Buy These 2 Stocks Before They Jump 80%, Say Analysts' Benzinga

Apr 6, 2021

03:18PM EDT Prometheus Biosciences shares were trading higher after multiple firms initiated coverage on the stock with bullish ratings. Benzinga

10:55AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2021 Benzinga

09:42AM EDT Guggenheim Initiates Coverage On Prometheus Biosciences with Buy Rating, Announces Price Target of $40 Benzinga

08:22AM EDT Stifel Initiates Coverage On Prometheus Biosciences with Buy Rating, Announces Price Target of $25 Benzinga

06:51AM EDT SVB Leerink Initiates Coverage On Prometheus Biosciences with Outperform Rating, Announces Price Target of $34 Benzinga

06:13AM EDT Credit Suisse Initiates Coverage On Prometheus Biosciences with Outperform Rating, Announces Price Target of $30 Benzinga

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

Mar 21, 2021

07:39AM EDT The Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More Benzinga

Mar 16, 2021

04:05PM EDT Prometheus Biosciences Announces Closing of Initial Public Offering and Full PR Newswire

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 12, 2021

02:42PM EST Mid-Afternoon Market Update: Dow Surges Over 200 Points; Prometheus Biosciences Shares Spike Higher Benzinga

11:55AM EST Prometheus Biosciences Shares Open For Trade At $24.95; IPO Priced At $19/Share Benzinga

09:25AM EST Prometheus Biosciences Shares Will Open For Quote At 11:00 a.m. EST, Expected To Open For Trade After 11:10 a.m. EST; IPO Priced At $19/Share Benzinga

Mar 11, 2021

10:36PM EST Prometheus Biosciences Prices Upsized IPO Of 10 Mln Common Shares At $19/Shr RTTNews

10:27PM EST Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering PR Newswire

Share